Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 2
2018 2
2020 1
2021 3
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Erratum for van der Laan et al., "Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis".
van der Laan LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, Winckler JL, Mao J, Draper HR, Wiesner L, Norman J, McIlleron H, Donald PR, Hesseling AC, Denti P. van der Laan LE, et al. Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0072023. doi: 10.1128/aac.00720-23. Epub 2023 Jun 20. Antimicrob Agents Chemother. 2023. PMID: 37338349 Free PMC article. No abstract available.
Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
van der Laan LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, Winckler JL, Mao J, Draper HR, Wiesner L, Norman J, McIlleron H, Donald PR, Hesseling AC, Denti P. van der Laan LE, et al. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0226421. doi: 10.1128/aac.02264-21. Epub 2022 May 4. Antimicrob Agents Chemother. 2022. PMID: 35506699 Free PMC article.
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Radtke KK, Hesseling AC, Winckler JL, Draper HR, Solans BP, Thee S, Wiesner L, van der Laan LE, Fourie B, Nielsen J, Schaaf HS, Savic RM, Garcia-Prats AJ. Radtke KK, et al. Among authors: van der laan le. Clin Infect Dis. 2022 Apr 28;74(8):1372-1381. doi: 10.1093/cid/ciab641. Clin Infect Dis. 2022. PMID: 34286843 Free PMC article.
Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial.
Garcia-Prats AJ, Svensson EM, Winckler J, Draper HR, Fairlie L, van der Laan LE, Masenya M, Schaaf HS, Wiesner L, Norman J, Aarnoutse RE, Karlsson MO, Denti P, Hesseling AC. Garcia-Prats AJ, et al. Among authors: van der laan le. J Antimicrob Chemother. 2021 Nov 12;76(12):3237-3246. doi: 10.1093/jac/dkab336. J Antimicrob Chemother. 2021. PMID: 34529779 Free PMC article. Clinical Trial.
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
Denti P, Wasmann RE, van Rie A, Winckler J, Bekker A, Rabie H, Hesseling AC, van der Laan LE, Gonzalez-Martinez C, Zar HJ, Davies G, Wiesner L, Svensson EM, McIlleron HM. Denti P, et al. Among authors: van der laan le. Clin Infect Dis. 2022 Aug 24;75(1):141-151. doi: 10.1093/cid/ciab908. Clin Infect Dis. 2022. PMID: 34665866 Free PMC article.
18 results